-
- Irene Rius Ruiz
- Preclinical Research Program, Vall d’Hebron Institute of Oncology (VHIO), 08035 Barcelona, Spain.
-
- Rocio Vicario
- Preclinical Research Program, Vall d’Hebron Institute of Oncology (VHIO), 08035 Barcelona, Spain.
-
- Beatriz Morancho
- Preclinical Research Program, Vall d’Hebron Institute of Oncology (VHIO), 08035 Barcelona, Spain.
-
- Cristina Bernadó Morales
- Preclinical Research Program, Vall d’Hebron Institute of Oncology (VHIO), 08035 Barcelona, Spain.
-
- Enrique J. Arenas
- Preclinical Research Program, Vall d’Hebron Institute of Oncology (VHIO), 08035 Barcelona, Spain.
-
- Sylvia Herter
- Roche Innovation Center Zurich, Roche Pharmaceutical Research and Early Development, Wagistrasse 18, 8952 Schlieren, Switzerland.
-
- Anne Freimoser-Grundschober
- Roche Innovation Center Zurich, Roche Pharmaceutical Research and Early Development, Wagistrasse 18, 8952 Schlieren, Switzerland.
-
- Jitka Somandin
- Roche Innovation Center Zurich, Roche Pharmaceutical Research and Early Development, Wagistrasse 18, 8952 Schlieren, Switzerland.
-
- Johannes Sam
- Roche Innovation Center Zurich, Roche Pharmaceutical Research and Early Development, Wagistrasse 18, 8952 Schlieren, Switzerland.
-
- Oliver Ast
- Roche Innovation Center Zurich, Roche Pharmaceutical Research and Early Development, Wagistrasse 18, 8952 Schlieren, Switzerland.
-
- Águeda Martinez Barriocanal
- Preclinical Research Program, Vall d’Hebron Institute of Oncology (VHIO), 08035 Barcelona, Spain.
-
- Antonio Luque
- Preclinical Research Program, Vall d’Hebron Institute of Oncology (VHIO), 08035 Barcelona, Spain.
-
- Marta Escorihuela
- Preclinical Research Program, Vall d’Hebron Institute of Oncology (VHIO), 08035 Barcelona, Spain.
-
- Ismael Varela
- Preclinical Research Program, Vall d’Hebron Institute of Oncology (VHIO), 08035 Barcelona, Spain.
-
- Isabel Cuartas
- Translational Research Program, VHIO, 08035 Barcelona, Spain.
-
- Paolo Nuciforo
- Clinical Research Program, VHIO, 08035 Barcelona, Spain.
-
- Roberta Fasani
- Clinical Research Program, VHIO, 08035 Barcelona, Spain.
-
- Vicente Peg
- Centro de Investigación Biomédica en Red de Cáncer (CIBERONC), 08035 Barcelona, Spain.
-
- Isabel Rubio
- Vall d’Hebron University Hospital, 08035 Barcelona, Spain.
-
- Javier Cortés
- Clinical Research Program, VHIO, 08035 Barcelona, Spain.
-
- Violeta Serra
- Preclinical Research Program, Vall d’Hebron Institute of Oncology (VHIO), 08035 Barcelona, Spain.
-
- Santiago Escriva-de-Romani
- Clinical Research Program, VHIO, 08035 Barcelona, Spain.
-
- Jeff Sperinde
- Monogram Biosciences, Laboratory Corporation of America Holdings, South San Francisco, CA 94080, USA.
-
- Ahmed Chenna
- Monogram Biosciences, Laboratory Corporation of America Holdings, South San Francisco, CA 94080, USA.
-
- Weidong Huang
- Monogram Biosciences, Laboratory Corporation of America Holdings, South San Francisco, CA 94080, USA.
-
- John Winslow
- Monogram Biosciences, Laboratory Corporation of America Holdings, South San Francisco, CA 94080, USA.
-
- Joan Albanell
- Centro de Investigación Biomédica en Red de Cáncer (CIBERONC), 08035 Barcelona, Spain.
-
- Joan Seoane
- Centro de Investigación Biomédica en Red de Cáncer (CIBERONC), 08035 Barcelona, Spain.
-
- Maurizio Scaltriti
- Department of Pathology, Human Oncology and Pathogenesis Program, Memorial Sloan Kettering Cancer Center, New York, NY 10065, USA.
-
- Jose Baselga
- Department of Medicine, Human Oncology and Pathogenesis Program, Memorial Sloan Kettering Cancer Center, New York, NY 10065, USA.
-
- Josep Tabernero
- Centro de Investigación Biomédica en Red de Cáncer (CIBERONC), 08035 Barcelona, Spain.
-
- Pablo Umana
- Roche Innovation Center Zurich, Roche Pharmaceutical Research and Early Development, Wagistrasse 18, 8952 Schlieren, Switzerland.
-
- Marina Bacac
- Roche Innovation Center Zurich, Roche Pharmaceutical Research and Early Development, Wagistrasse 18, 8952 Schlieren, Switzerland.
-
- Cristina Saura
- Clinical Research Program, VHIO, 08035 Barcelona, Spain.
-
- Christian Klein
- Roche Innovation Center Zurich, Roche Pharmaceutical Research and Early Development, Wagistrasse 18, 8952 Schlieren, Switzerland.
-
- Joaquín Arribas
- Preclinical Research Program, Vall d’Hebron Institute of Oncology (VHIO), 08035 Barcelona, Spain.
抄録
<jats:p>T cell bispecific antibodies against an isoform of HER2 effectively target many HER2-expressing tumors but not normal tissues.</jats:p>
収録刊行物
-
- Science Translational Medicine
-
Science Translational Medicine 10 (461), 2018-10-03
American Association for the Advancement of Science (AAAS)